What Is Tesamorelin?
Tesamorelin (brand name Egrifta) is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has received FDA approval specifically for reducing visceral adipose tissue (VAT) — the dangerous deep belly fat that surrounds internal organs and is associated with metabolic syndrome, cardiovascular disease, and insulin resistance.
While originally studied and approved for HIV-associated lipodystrophy, tesamorelin's mechanism of action makes it valuable for any patient struggling with excess visceral fat — particularly those who have not responded adequately to diet and exercise alone.
Why Visceral Fat Is Dangerous
Not all fat is equal. Subcutaneous fat (under the skin) is largely cosmetic. Visceral fat — the fat around your internal organs — is metabolically active and harmful:
- Secretes inflammatory cytokines that damage blood vessels and organs
- Strongly associated with type 2 diabetes and insulin resistance
- Linked to cardiovascular disease, stroke, and heart attack
- Associated with non-alcoholic fatty liver disease
- Contributes to hormonal imbalance
Reducing visceral fat isn't just cosmetic — it's one of the most important things you can do for your long-term health.
How Tesamorelin Targets Belly Fat
- Stimulates pituitary to increase growth hormone secretion
- Elevated GH specifically mobilizes visceral fat stores (preferential fat burning)
- Increases IGF-1, which supports lean muscle preservation during fat loss
- Improves lipid profiles (reduced triglycerides, improved HDL)
- Reduces inflammatory markers associated with visceral fat
Clinical Evidence for Tesamorelin
Phase III clinical trials (the trials that led to FDA approval) demonstrated:
- 15–20% reduction in visceral fat measured by CT scan over 6 months
- Significant reductions in waist circumference
- Improved triglyceride levels
- Enhanced trunk-to-limb fat ratio (improved body composition)
- Effects maintained with continued therapy
Tesamorelin at Kanvas Wellness, Hendersonville TN
Your tesamorelin journey at Kanvas Wellness begins with a comprehensive metabolic evaluation. We establish your baseline measurements, review your health history, and determine if tesamorelin is appropriate for your goals. Treatment involves once-daily subcutaneous injection, and we provide complete guidance and follow-up monitoring throughout your protocol.
Medical Disclaimer
Tesamorelin requires a prescription and medical supervision. Contraindicated in patients with active malignancy, pregnancy, or certain pituitary disorders. May affect glucose metabolism — regular monitoring recommended for diabetic patients. Individual results vary. Off-label use outside of HIV lipodystrophy is not FDA-endorsed.